Incretin based drugs and the risk of pancreatic cancer: International multicentre cohort study

The BMJ

Volumn 352, Issue , 2016, Pages

  Azoulay, Laurent ^a,b   Filion, Kristian B ^a,b   Platt, Robert W ^c   Dahl, Matthew ^d,e   Dormuth, Colin R ^f   Clemens, Kristin K ^g   Durand, Madeleine ^h   Juurlink, David N ⁱ   Targownik, Laura E ^d,j   Turin, Tanvir C ^k   Paterson, J Michael ^i,l   Ernst, Pierre ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^j UNIVERSITY OF MANITOBA   (Canada)

^k UNIVERSITY OF CALGARY   (Canada)

^l UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; INSULIN; MEGLITINIDE; METFORMIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ADULT; AGED; ARTICLE; CANADA; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL COOPERATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES; YOUNG ADULT; AGONISTS; CASE CONTROL STUDY; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

ADULT; AGED; CANADA; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; UNITED KINGDOM; UNITED STATES; YOUNG ADULT;

EID: 84960154441     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i581     Document Type: Article

References (35)

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-39. doi:10.1152/physrev.00034.2006.
2. Gale EA. GLP-1-based therapies and the exocrine pancreas: more light, or just more heat?Diabetes 2012;61:986-8. doi:10.2337/db11-1838.
3. Kabuzek K, Kozowski M, Szkudapski D, Sikorska P, Kozowska M, Okopie B. Incretin-based therapies in the treatment of type 2 diabetes-more than meets the eyeEur J Intern Med 2013;24:207-12. doi:10.1016/j.ejim.2013.01.009.
4. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-6. doi:10.1053/j. gastro.2011.02.018. 21334333.
5. Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-Analysis. BMC Endocr Disord 2010;10:20. doi:10.1186/1472-6823-10-20.
6. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-Analysis of randomized clinical trials. Curr Med Res Opin 2011;27(Suppl 3):57-64. doi:10.1185/03007995.2 011.602964.
7. Jeong KH, Yoo BK. The efficacy and safety of liraglutide. Int J Clin Pharm 2011;33:740-9. doi:10.1007/s11096-011-9552-8.
8. Scirica BM, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26. doi:10.1056/NEJMoa1307684.
9. White WB, Cannon CP, Heller SR, et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35. doi:10.1056/NEJMoa1305889.
10. Green JB, Bethel MA, Armstrong PW, et al. TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-42. doi:10.1056/NEJMoa1501352.
11. Pfeffer MA, Claggett B, Diaz R, et al. ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-57. doi:10.1056/NEJMoa1509225.
12. Dore DD, Seeger JD, Chan KA. Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance. Ther Adv Drug Saf 2012;3:157-64. doi:10.1177/2042098612446473.
13. Romley JA, Goldman DP, Solomon M, McFadden D, Peters AL. Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol Ther 2012;14:904-11. doi:10.1089/dia.2012.0075.
14. Funch D, Gydesen H, Tornøe K, Major-Pedersen A, Chan KA. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes Metab 2014;16:273-5. doi:10.1111/dom.12230.
15. Gokhale M, Buse JB, Gray CL, Pate V, Marquis MA, Stürmer T. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. Diabetes Obes Metab 2014;16:1247-56. doi:10.1111/dom.12379.
16. Tseng CH. Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes. Eur J Clin Invest 2016;46:70-9. doi:10.1111/eci.12570.
17. Knapen LM, van Dalem J, Keulemans YC, et al. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study. Diabetes Obes Metab 2015; published online 5 November. doi:10.1111/dom.12605.
18. Azoulay L. Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains. Diabetes Care 2015;38:951-3. doi:10.2337/dc15-0347.
19. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med 2014;370:794-7. doi:10.1056/NEJMp1314078.
20. Suissa S, Henry D, Caetano P, et al. Canadian Network for Observational Drug Effect Studies (CNODES). CNODES: the Canadian Network for Observational Drug Effect Studies. Open Med 2012;6:e134-40.
21. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015;44:827-36. doi:10.1093/ije/dyv098.
22. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009;10:88-95. doi:10.1016/S1470-2045(08)70337-1.
23. Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom B, ed. Pharmacoepidemiology.4th ed. Wiley, 2005: 811-29.
24. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005;5:5. doi:10.1186/1471-2288-5-5.
25. Suissa S. The quasi-cohort approach in pharmacoepidemiology: upgrading the nested case-control. Epidemiology 2015;26:242-6. doi:10.1097/EDE.0000000000000221.
26. Hall S, Schulze K, Groome P, Mackillop W, Holowaty E. Using cancer registry data for survival studies: the example of the Ontario Cancer Registry. J Clin Epidemiol 2006;59:67-76. doi:10.1016/j. jclinepi.2005.05.001.
27. Inzucchi SE, Bergenstal RM, Buse JB, et al. American Diabetes Association (ADA) European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79. doi:10.2337/dc12-0413.
28. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012;35:2665-73. doi:10.2337/dc12-0788.
29. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. doi:10.1056/NEJMoa072761.
30. Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012;344:e3645. doi:10.1136/bmj.e3645.
31. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154:854-64. doi:10.1093/aje/154.9.854. 11682368.
32. DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin Trials 1986;7:177-88. doi:10.1016/0197-2456(86)90046-2.
33. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-20. doi:10.1093/aje/kwg231.
34. Johnson JA, Bowker SL, Richardson K, Marra CA. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 2011;54:2263-71. doi:10.1007/s00125-011-2242-1.
35. Benoit SR, Fleming R, Philis-Tsimikas A, Ji M. Predictors of glycemic control among patients with type 2 diabetes: a longitudinal study. BMC Public Health 2005;5:36. doi:10.1186/1471-2458-5-36.